BackProPhase Labs Overview

ProPhase Labs Current Cash

ProPhase Labs's current cash is $31K.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$31000.00
↓ 64.77% YoYΔ $-57000.00 vs prior year quarter

Peer trimmed avg / median

Loading

ProPhase Labs Current Cash History

Loading

ProPhase Labs vs. peers: Current Cash Comparison

Loading

ProPhase Labs Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

ProPhase Labs (PRPH) FAQ

ProPhase Labs (PRPH) currently reports a current cash of $31K as of March 2026. That compares with $88K in the prior-year period — down 64.8% year over year. Use the charts on this page to explore ProPhase Labs's current cash history and peer comparisons.

ProPhase Labs's current cash decreased from $88K to $31K — a 64.8% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ProPhase Labs reported $31K in current cash as of March 2026. That compares with $88K in the prior-year period — down 64.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $31K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ProPhase Labs, and consider following PRPH for alerts when major investors trade the stock.

ProPhase Labs is classified in the Healthcare sector. On current cash, it currently shows $31K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PRPH with unrelated industries.